BSD's MicroThermX Gains Acceptance

Cancer treatment systems maker BSD Medical Corp. (BSDM) recently revealed acceptance of its MicroThermX Microwave Ablation System (“MicroThermX”) at the World Conference on Interventional Oncology (“WCIO”) convened in New York City, between June 9 and 12, 2011. The two technical presentations, showcasing the benefits of the MicroThermX system, were the cynosure of the WCIO convention.

The WCIO gathering was attended by participants from across the globe. It concentrated on the usage of less invasive treatments for cancer. In this regard, the meeting focused on the usage of microwave ablation as the first-choice, minimally-invasive therapy for cancer. The meeting was graced by important opinion makers from across the globe.

Two researchers from Brown University/Rhode Island Hospital provided testing information, as a part of the conference’s scientific presentations, showing that the unusual “synchronous phased array” capacity of the lone generator MicroThermX produced bigger ablation zones versus the “competing asynchronous multi-generator” know-how.

A BSD ablation engineer showed testing outcome to the conference attendees, revealing that the danger of skin burn due to non-parallel positioning of several microwave antennas can be sharply cut down by  the usage of the synchronous phased array capacity of the MicroThermX (versus other asynchronous ablation know-how). Skin burn is a complication arising from ablation that may take several months to repair.

Interventional oncology is a growth area of interventional radiology concentrating on the delivery of cancer therapy, including ablation treatment, which directly targets the tumor without huge side -effects or harm to neighboring healthy tissue.

BSD Medical competes with established players like Boston Scientific (BSX - Analyst Report) and Angiodynamics (ANGO - Analyst Report) in the thermal ablation market. The global market potential for soft tissue ablation has been estimated to exceed $2.3 billion, offering a significant opportunity for BSD Medical.

Read the full analyst report on BSX

Read the full analyst report on ANGO

Read the full analyst report on BSDM